Super-Energizer and Potent Antioxidant
CoQ10 is a naturally-occurring antioxidant produced in the human body. It is vitally involved in energy production. CoQ10 functions as an “energizer” to mitochondria, the body’s energy producing units. Mitochondria, which produce energy the body’s “energy currency,” ATP, require CoQ10 to “spark” their production of energy units (ATP). Muscles, and the heart in particular, have high requirements for CoQ10.
CoQ10 is a potent antioxidant beneficial for:
- Heart Disease (angina, arrhythmia, atherosclerosis, cardiomyopathy, heart failure, congestive heart failure, myocardial infarction (1-18)
- High Blood Pressure (1,3,4,14, 53, 55)
- Neurological disease (Alzheimer’s, Huntington’s, Parkinson’s) (19-37)
- Immune deficiency and AIDS (40-45,52)
- Periodontal disease (38-39)
- Cancer (40, 44-49)
- Chemotherapy side-effects (50-52)
- Diabetes (53-56)
- Muscular dystrophy (57-58)
- fatigue / chronic fatigue / fibromyalgia (59-61)
- migraine headache (62-63)
- enhancing athletic performance (64-68)
- male infertility (69-73)
CoQ10 is produced by the body, but age, nutrient deficiencies, disease and some medications can lower the body’s CoQ10 levels. Cholesterol-lowering drugs (statins) deplete CoQ10. (15,54,74-77)
Studies have shown that the oil-preserved form is up to 3 times better absorbed than other forms. (78-80)
Although many claims are currently made for a “new” form (ubiquinol) being “more absorbable” than ubiquinone, this has never been proven or well-studied. Learn more about this issue here:Ubiquinone (CoQ10) versus Ubiquinol: Which Is Better?
CoQ10 and it’s use in CHF (Congestive Heart Failure):
“… Coenzyme Q10 (CoQ10) is essential for electron transport within the mitochondria and hence for ATP generation and cellular energy production. We recently demonstrated that plasma levels of CoQ10 are an independent predictor of survival in a cohort of 236 patients with chronic heart failure (CHF) followed for a median of 2.69 years. This is consistent with previous studies which have shown myocardial CoQ10 depletion in CHF, and correlated with the severity of the underlying disorder. Several intervention studies have been undertaken with CoQ10 in CHF, including randomized controlled trials with mostly positive outcomes in relation to improvement in plasma levels of CoQ10. A meta-analysis showed that CoQ10 resulted in an improvement in ejection fraction of 3.7% (95%CI 1.59-5.77) and the mean increase in cardiac output was 0.28 L/minute (95%CI 0.03-0.53). In a subgroup analysis, studies with patients not taking ACE inhibitors found a 6.7% increase in ejection fraction. The ongoing Q-SYMBIO trial will address whether CoQ10 supplementation improves survival in CHF patients. CoQ10 depletion may also be a contributory factor for why statin intervention has not improved outcomes in CHF. There is an emerging evidence base in support of CoQ10 as an adjunctive therapy in CHF.”
“…The majority of the clinical studies concerned the treatment of heart disease and were remarkably consistent in their conclusions: that treatment with CoQ10 significantly improved heart muscle function while producing no adverse effects or drug interactions. …”
Dr. Myatt’s Conclusion:
CoQ10 is beneficial for nearly every type of Heart Disease (angina, arrhythmia, atherosclerosis, cardiomyopathy, heart failure, congestive heart failure, myocardial infarction (1-18)
50-100 mg per day for health maintenance and anti-aging / longevity programs.
200 to 400 mg per day for heart problems, cancer, weight loss programs and other indications.
Studies performed by the National Institutes of Health (NIH) using Vitaline ™ brand CoQ10, have used 300-400 mg (or more under medical direction) per day.
Each Capsule contains:
50 or 100 mg capsules are Wellness Club brand oil-preserved CoQ10 in easy to swallow gel Caps with Vitamin E & Beta carotene as natural preservatives.
300 and 400mg tablets are Vitaline/Integrative Therapeutics chewable wafers, the exact formulas used in the NIH Parkinson’s trials.
Product # 134 Wellness Club CoQ10 (60 softgel Caps 50 mg) 35.95
Product # 135 Wellness Club (60 softgel Caps 100 mg) 62.95
Vitaline brand CoQ10 is THE CoQ10 that has been the subject of NIH studies and a recent trial showing its potential value in Parkinson’s patients.
Co10 has been shown to be potentially helpful for:
- neurological health
- cardiovascular health
- anti-aging and longevity
NOTE: Vitaline® brand CoQ10 is available under several different labels.
is the “Doctors Only” label
is the “Health Food Store” label
|Vitaline under the “Vitaline Formulas” Label is the same product|
THESE ARE ALL THE EXACT SAME PRODUCT That Is Used In The NIH Studies
All are made by Vitaline and given different labels.
Vitaline, Vitamin E, and Vitamin E safety:
Some people (including some doctors) have a mistaken fear of Vitamin E, believing that “too much is dangerous.”
We have been unable to find any evidence in medical or scientific literature of any danger from taking large doses of Vitamin E. The National Institutes for Health (NIH) a US government authority places the maximum daily intake of Vitamin E at 1500 IU for healthy adults.
High intake of Vitamin E intake does tend to “thin” the blood, affecting coagulation by inhibiting platelet aggregation. People using antigoagulants or who bleed too easily may wish to discuss the use of Vitamin E with theri doctor.It has also been reported that Vitamin E in high doses may block the action of Vitamin K which is known as “the clotting factor.”
According to the label information and the Enzymatic Therapy website:
Vitaline® CoQ10 – 300 mg WITH Vitamin E contains 300 IU Vitamin E per chewable tab.
Vitaline® CoQ10 – 400 mg WITH Vitamin E contains 200 IU Vitamin E per chewable tab.
In order to achieve the daily intake of Vitamin E that you or your health care provider wish you to have you can either use a different tablet strength, either 300 or 400 mg to achieve 1200mg per day or mix your intake between Vitaline WITH and Vitaline WITHOUT Vitamin E to achieve your preferred daily intake of Vitamin E.
1.) Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. 2008;32(1-4):145-9.
2.) Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, Vered Y, Vidne BA, Aravot D. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004 May;27(5):295-9.
3.) Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002 Nov;56(11):1137-42.
4.) Kumar A, Kaur H, Devi P, Mohan V. Role of Coenzyme Q10 (CoQ10) in Cardiac disease, Hypertension and Meniere- like syndrome. Pharmacol Ther. 2009 Jul 25. [Epub ahead of print]
5.) Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React. 1990;12(3):163-8.
6.) Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr. 1988 Jul 1;66(13):583-90.
7.) Langsjoen P, Langsjoen A, Willis R, and Folkers K. The Aging Heart: Reversal of Diastolic Dysfunction Through the Use of Oral CoQ10 in the Elderly. Anti-Aging Medical Therapeutics. Klatz RM and Goldman R (eds.). Health Quest Publications. 1997;113-120.
8.) Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med. 1997;18(S):s145-s151.
9.) Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4240-4.
10.) Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J, Kobayashi J. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. Journal of Atheroscler Thromb. 2005;12(2):111-9.
11.) Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008 Oct 28;52(18):1435-41.
12.) Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of “Q-symbio”–a multinational trial. Biofactors. 2003;18(1-4):79-89.
13.) Mortensen S.A., Vadhanavikit S., Muratsu K., Folkers K. (1990) Coenzyme Q10: Clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. In: Int. J. Tissue React., Vol. 12 (3), pp 155-162.
14.) Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension, and heart failure. Biofactors. 2003;18(1-4):91-100.
15.) Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004 Nov 15;94(10):1306-10.
16.) Singh RB; Wander GS et al Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther, 12(4):347-53 1998 Sep.
17.) Singh RB; Wander GS et al Cardiovasc Drugs Ther, 12(4):347-53 1998 Sep.
18.) Weant KA, Smith KM. The role of coenzyme Q10 in heart failure. Ann Pharmacother. 2005;39(9):1522-6.
19.) Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res. 2002 Apr;36(4):455-60.
20.) Fallon J, Matthews RT, Hyman BT, Beal MF. MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress. Exp Neurol. 1997 Mar;144(1):193-8.
21.) Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington’s disease. Mov Disord. 1996;11(3):321-323.
22.) Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005 Dec 13;65(11):1834-1836.
23.) Flint Beal M, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783:109-114.
24.) Flint Beal M, Matthews RT. Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol Aspects Med. 1997;18(S);s169-s179.
25.) Flint Beal M, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol. 1994;36:882-888.
26.) Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, Rosen BR. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab. 1996 May;16(3):450-61.
27.) Koroshetz WJ, Jenkins BG, Rosen BR, Flint Beal M. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol. 1997;41:160-165.
28.) Matthews RT, Yang L, Brown S, Baik MF. Coenzyme Q10 administration increases brain mitochondrial concentration and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998;95:8892-8897.
29.) Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington’s disease transgenic mouse model. Neurosci Lett. 2001 Nov 27;315(3):149-53.
30.) Shults CW, Oakes D, Kieburtz K, et al. Effects of Coenzyme Q10 in Early Parkinson’s Disease. Arch Neurol. 2002:59:1541-1550.
31.) Schulz B, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 1996;71(4):1043-1048.
32.) Shults CW, Flint Beal M, Fontaine D, Nakano K, Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology. 1998;50:793-795.
33.) Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997 Aug;42(2):261-4.
34.) Schulz JB, Henshaw R, Matthews RT, Flint Beal M. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995;132:279-283.
35.) Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp Neurol. 2004 Aug;188(2):491-4.
36.) The Huntington Study Group. A Randomized, Placebo-Controlled Trial of Coenzyme Q10 and Remacemide in Huntington’s Disease. Neurology. 2001:57:397-404.
37.) Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem. 2009 Jun;109(5):1427-39.
38.) Hanioka T, Tanaka M, Ojima M, Shizukuishi S, Folkers K. Effect of topical application of coenzyme Q10 on adult periodontitis. Mol Aspects Med. 1994;15 Suppl:s241-8.
39.)Nakamura R, Littarru GP, Folkers K, Wilkinson EG. Study of CoQ10-enzymes in gingiva from patients with periodontal disease and evidence for a deficiency of coenzyme Q10. Proc Natl Acad Sci U S A. 1974 Apr;71(4):1456-60.
40.) Folkers K, Hanioka T, Xia LJ, McRee JT Jr, Langsjoen P. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun. 1991 Apr 30;176(2):786-91.
41.) Folkers K, Langsjoen P, Nara Y, Muratsu K, Komorowski J, Richardson PC, Smith TH. Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment. Biochem Biophys Res Commun. 1988 Jun 16;153(2):888-96.
42.) Folkers K, Wolaniuk A. Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res. 1985;11(8):539-45.
43.) Ravaglia G, Forti P, Maioli F, Bastagli L, Facchini A, Mariani E, Savarino L, Sassi S, Cucinotta D, Lenaz G. Effect of micronutrient status on natural killer cell immune function in healthy free-living subjects aged >/=90 y. Am J Clin Nutr. 2000 Feb;71(2):590-8.
44.) Folkers K, Morita M, McRee J Jr. The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochem Biophys Res Commun. 1993 May 28;193(1):88-92.
45.) Folkers K, Brown R, Judy WV, Morita M. Biochem Biophys Res Commun. 1993 Apr 15;192(1):241-5.Survival of cancer patients on therapy with coenzyme Q10.
46.) Judy WV. Nutritional intervention in cancer prevention and treatment. American College for Advancement in Medicine Spring Conference, Ft. Lauderdale, FL. May 3, 1998.
47.) Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994;199:1504–8.
47.) Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med. 1994;15 Suppl:s231-40.
48.) Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172–7.
49.) Perumal SS, Shanthi P, Sachdanandam P. Energy-modulating vitamins–a new combinatorial therapy prevents cancer cachexia in rat mammary carcinoma.Br J Nutr. 2005 Jun;93(6):901-9.
50.) Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther. 2005 Jun;4(2):110-30.
51.) Domae N, Sawada H, Matsuyama E, Konishi T, Uchino H. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):79-91.
52.) Folkers K, Wolaniuk A. Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp Clin Res. 1985;11(8):539-45.
53.) Chew GT, Watts GF, Davis TM, Stuckey BG, Beilin LJ, Thompson PL, Burke V, Currie PJ. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care. 2008 Aug;31(8):1502-9. Epub 2008 May 16.
54.) Hamilton SJ, Chew GT, Watts GF. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care. 2009 May;32(5):810-2. Epub 2009 Feb 19.
55.) Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002 Nov;56(11):1137-42.
56.) Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. 2002 Mar;45(3):420-6.
57.) Folkers K, Simonsen R.Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta. 1995 May 24;1271(1):281-6.
58.) Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S.Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4513-6.
59.) Bentler SE, Hartz AJ, Kuhn EM. Prospective observational study of treatments for unexplained chronic fatigue. J Clin Psychiatry. 2005 May;66(5):625-32.
60.) Cordero MD, Moreno-Fernández AM, deMiguel M, Bonal P, Campa F, Jiménez-Jiménez LM, Ruiz-Losada A, Sánchez-Domínguez B, Sánchez Alcázar JA, Salviati L, Navas P. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia. Clin Biochem. 2009 May;42(7-8):732-5. Epub 2008 Dec 25.
61.) Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res. 2002 Mar-Apr;30(2):195-9.
62.) Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005 Feb 22;64(4):713-5.
63.) Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia. 2002 Mar;22(2):137-41.
64.) Cohen B, Gold D. Mitochondrial cytopathy in adults: What we know so far. Cleveland Clinic J Medicine 2001, 68:7,625-642.
65.) Cooke M, Iosia M, Buford T, Shelmadine B, Hudson G, Kerksick C, Rasmussen C, Greenwood M, Leutholtz B, Willoughby D, Kreider R.Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals. J Int Soc Sports Nutr. 2008 Mar 4;5:8.
66.) Gökbel H, Gül I, Belviranl M, Okudan N. The Effects Of Coenzyme Q10 Supplementation on Performance During Repeated Bouts of Supramaximal Exercise in Sedentary Men. J Strength Cond Res. 2009 Jul 28. [Epub ahead of print]
67.) Kon M, Tanabe K, Akimoto T, Kimura F, Tanimura Y, Shimizu K, Okamoto T, Kono I. Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10. Br J Nutr. 2008 Feb 20;1-7. 68.) Mizuno K, Tanaka M, Nozaki S, Mizuma H, Ataka S, Tahara T, Sugino T, Shirai T, Kajimoto Y, Kuratsune H, Kajimoto O, Watanabe Y. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition. 2008 Feb 11.
69.) Balercia G, Buldreghini E, Vignini A, Tiano L, Paggi F, Amoroso S, Ricciardo-Lamonica G, Boscaro M, Lenzi A, Littarru G. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil Steril. 2009 May;91(5):1785-92. 70.) Balercia G, Mancini A, Paggi F, Tiano L, Pontecorvi A, Boscaro M, Lenzi A, Littarru GP. COENZYME Q10 AND MALE INFERTILITY. J Endocrinol Invest. 2009 May 21. [Epub ahead of print]
71.) Balercia G, Mosca F, Mantero F, Boscaro M, Mancini A, Ricciardo-Lamonica G, Littarru G. Coenzyme Q(10) supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril. 2004 Jan;81(1):93-8.
72.) Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007 Sep;37(1):31-7.
73.) Mancini A, De Marinis L, Littarru GP, Balercia G. An update of Coenzyme Q10 implications in male infertility: biochemical and therapeutic aspects. Biofactors. 2005;25(1-4):165-74.
74.) Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009 Jun 16;150(12):858-68.
75.) Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003;18(1-4):101-11.
76.) Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors. 2005;25(1-4):147-52.
77.) Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007 May 15;99(10):1409-12. Epub 2007 Apr 3.
78.) Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007 Jun;7 Suppl:S78-88. Epub 2007 Mar 27.
79.) Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res 1998;68:109–13.
80.)Weiss M, Mortensen SA, Rassig MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Molec Aspects Med 1994;15:273–80.